ArticleWiener klinische Wochenschrift2026
Systemic lupus erythematosus combined with Castleman disease: a case report.
Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Astragaloside IV Alleviates Lupus Nephritis by Inhibiting Podocyte Ferroptosis via the PI3K/AKT/Nrf2 Pathway.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE), a multisystemic autoimmune disorder, carries an increased risk of lymphoproliferative diseases, with overlapping clinical features often complicating diagnostic differentiation. We describe a 54-year-old woman with established SLE involving the skin, joints and kidneys (previously managed with prednisone, cyclophosphamide and hydroxychloroquine). Following self-discontinuation of prednisone treatment, the patient developed a disease flare manifesting as a labial rash and proteinuria. Renal histopathology confirmed persistent class V lupus nephritis. Computed tomography (CT) identified left axillary lymphadenopathy, with subsequent excisional biopsy revealing features diagnostic of Castleman disease. The coexistence of SLE and Castleman disease (CD) is relatively rare. Targeted immunosuppressive therapy with tacrolimus (TAC) and mycophenolate mofetil (MMF) resulted in clinical stabilization within 3 months of treatment initiation. Proteinuria decreased from 1.35 g/24 h to 0.24 g/24 h, with a concomitant reduction in lymph node size. Clinical improvement even in the absence of glucocorticoid induction therapy offers valuable insights for clinicians.
Indexed as
Identifiers
41428217What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.